



Disclosures

Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP General Cardiology</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
Daiichi Sankyo	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP General Cardiology</i>
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
fees for lecturing on apixaban from Bristol Myers-Squibb and Pfizer, and has been an investigator in the ARISTOTLE trial	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP General Cardiology</i>
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Roche	Research/Research Grants	Modest (< \$5,000)	<i>General Cardiology</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
Various trials on evolocumab	Amgen Inc.	
CANTOS	Novartis Corporation	
ATMOSPHERE	Novartis Corporation	

Institutional Financial Decision-Making Role (3)

Funding Source	Institutional Compensation Level
Bayer Healthcare Pharmaceuticals	Significant (>= \$5,000)
Boehringer Ingelheim Pharmaceuticals, Inc	Significant (>= \$5,000)
Pfizer	Significant (>= \$5,000)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/5/2017

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/5/2017

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/5/2017

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/5/2017

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.